Quick answer: Tirzepatide (Zepbound) produces more weight loss than semaglutide (Wegovy) on average: 20.2% vs 13.7% of body weight at 72 weeks in SURMOUNT-5, the only head-to-head trial. What changed in 2026: a higher semaglutide dose, Wegovy HD (7.2 mg), averaged 18.7% in its own trial, and two weight-loss pills arrived. So the gap now depends on which version you compare. Self-pay prices overlap too: Zepbound $299–$449 a month, Wegovy $349, Wegovy HD $399.
Tirzepatide and semaglutide are prescription GLP-1 medicines for weight loss and type 2 diabetes, taken mostly as once-weekly injections. Semaglutide (Wegovy, Ozempic, Rybelsus) copies one gut hormone, GLP-1; tirzepatide (Zepbound, Mounjaro) acts on two, GIP and GLP-1. Most semaglutide vs tirzepatide comparisons still stop at 2024 data. Below: every 2026 version, the odds of hitting each milestone, and who each drug suits. Every figure below is from the branded drugs' trials and labels.
- Tirzepatide averaged 20.2% weight loss and semaglutide 2.4 mg 13.7% in SURMOUNT-5, the only head-to-head trial; 48.4% vs 27.3% lost a fifth of their body weight.
- Wegovy HD (semaglutide 7.2 mg, approved March 2026) averaged 18.7% in a separate trial, for people who already tolerate 2.4 mg.
- Semaglutide (Wegovy) is approved to lower heart attack and stroke risk; tirzepatide (Zepbound) is approved for obstructive sleep apnea.
Tirzepatide vs semaglutide in 2026: every version compared
| Brand | How you take it | Average weight loss* | Lost 20% or more* | Self-pay price a month | FDA-approved for |
|---|---|---|---|---|---|
| Zepbound tirzepatide · Eli Lilly |
Weekly injection (pen or vial) | 20.2% at 72 weeks SURMOUNT-5, 10 or 15 mg, head-to-head with Wegovy |
48.4% of people | $299 at 2.5 mg, $399 at 5 mg, $449 at 7.5–15 mg (refilled within 45 days; $499–$699 if refilled later) Source: LillyDirect, checked Oct 11, 2026 |
Chronic weight management; moderate-to-severe obstructive sleep apnea in adults with obesity |
| Wegovy semaglutide 2.4 mg · Novo Nordisk |
Weekly injection (pen) | 13.7% at 72 weeks SURMOUNT-5, 1.7 or 2.4 mg, same trial as Zepbound |
27.3% of people | $349 at any dose up to 2.4 mg; $199 for the first two starter fills (new patients, through Dec 31, 2026) Source: Wegovy savings page (Novo Nordisk), checked Oct 11, 2026 |
Chronic weight management (adults and ages 12+); lowering heart attack and stroke risk in adults with heart disease and excess weight; MASH liver disease with moderate-to-advanced fibrosis (no cirrhosis) |
| Wegovy HD New Mar 2026 semaglutide 7.2 mg · Novo Nordisk |
Weekly injection, only after 4+ weeks on 2.4 mg | 18.7% at 72 weeks STEP UP, separate trial; the 2.4 mg arm lost 15.6% |
45.5% of people | $399 Source: Wegovy savings page (Novo Nordisk), checked Oct 11, 2026 |
Extra weight reduction in adults who tolerate 2.4 mg |
| Wegovy pill New Jan 2026 oral semaglutide 25 mg · Novo Nordisk |
Daily tablet, empty stomach, wait 30 minutes | 13.6% at 64 weeks OASIS 4, per the label, separate trial |
27.9% of people | $149 at 1.5 mg, $199 at 4 mg, $299 at 9 and 25 mg Source: Wegovy savings page (Novo Nordisk), checked Oct 11, 2026 |
Chronic weight management; lowering heart attack and stroke risk in adults with heart disease and excess weight |
| Foundayo New Apr 2026 orforglipron (a different molecule) · Eli Lilly |
Daily tablet, with or without food | 11.2% at 72 weeks ATTAIN-1, top dose, separate trial |
18.4% of people | $149 at 0.8 and 2.5 mg, $199 at 5.5 mg (the 2.5 and 5.5 mg prices are reduced through Dec 31, 2026), $299 at 9 mg and up (at 14.5 and 17.2 mg only if refilled within 45 days; $349 otherwise) Source: LillyDirect, checked Oct 11, 2026 |
Chronic weight management in adults |
*Includes people who stopped the drug early, so these averages are not just the people who stuck with it, and every row is measured the same way. Only Zepbound and Wegovy were compared in the same trial; the other rows are separate trials with different people and lengths, so read them as ballpark, not as a ranking. Prices are the manufacturers' self-pay prices for the medication only; you also need a prescriber.
Choosing between brands rather than molecules? See Zepbound vs Wegovy for prices, pens, vials and coverage, or Foundayo vs Zepbound for the daily pill against the weekly shot.
Is semaglutide or tirzepatide better?
For weight loss alone, tirzepatide is better on average: it beat semaglutide 2.4 mg by about 6.5 percentage points of body weight in SURMOUNT-5, and nearly twice as many people lost 20% or more. Semaglutide can be the better choice for a specific person: Wegovy is the one approved to lower heart attack and stroke risk and to treat MASH liver disease, it comes as a daily pill, it may be the drug your insurance covers, and Wegovy HD (7.2 mg) narrows the gap for people already taking it. Side effects are similar. Neither is better for everyone, and the situations below are where the choice usually turns.
How much weight will you lose? Your odds, not just the average
Tirzepatide posts higher average weight-loss numbers than semaglutide in clinical trials, and SURMOUNT-5 also reported how many people crossed each milestone:
| Lost at least | Tirzepatide (Zepbound) | Semaglutide (Wegovy) |
|---|---|---|
| 10% of body weight | 81.6% | 60.5% |
| 15% of body weight | 64.6% | 40.1% |
| 20% of body weight | 48.4% | 27.3% |
| 25% of body weight | 31.6% | 16.1% |
About 5 in 10 people on tirzepatide lost a fifth of their body weight, against about 3 in 10 on semaglutide. At the low end, about 18% of the tirzepatide group and about 40% of the semaglutide group lost less than 10%. Real-world data point the same way: among 18,386 matched adults using the diabetes-labelled versions, 42.3% on tirzepatide and 18.1% on semaglutide reached 15% loss within a year, although more than half stopped treatment along the way (Rodriguez et al., JAMA Internal Medicine, 2024). For the full ranking across every GLP-1, see Which GLP-1 Is Most Effective for Weight Loss?
Has Wegovy HD closed the gap?
Closer, but not proven. Wegovy HD is semaglutide at 7.2 mg once weekly, approved by the FDA in March 2026. In the STEP UP trial, it averaged 18.7% weight loss at 72 weeks (15.6% on 2.4 mg), and 45.5% of people lost at least 20%. That is close to tirzepatide's 20.2%, but STEP UP never included tirzepatide. Trial populations matter: Wegovy 2.4 mg averaged 15.6% in STEP UP but 13.7% in SURMOUNT-5, so the real gap between 7.2 mg and tirzepatide is unknown. (In SURMOUNT-5, people on the 15 mg tirzepatide dose averaged 21.8%, versus 15.4% on 2.4 mg semaglutide.)
- Who can get it: only adults who have tolerated 2.4 mg for at least 4 weeks and need more weight loss. It is not a starting dose.
- The trade-off: more side effects. Stomach and gut side effects hit 70.8% on 7.2 mg versus 61.2% on 2.4 mg, and 22.9% reported unusual skin sensations such as tingling (6.0% on 2.4 mg).
- Price: $399 a month self-pay, $50 more than standard Wegovy.
If you are on Wegovy 2.4 mg and stalled, Wegovy HD and a switch to tirzepatide are now both real options to raise with your prescriber. See our Ozempic vs Wegovy explainer for how the semaglutide brands differ.
What is the difference between semaglutide and tirzepatide?
The main difference: semaglutide mimics one gut hormone (GLP-1), while tirzepatide mimics two (GIP and GLP-1). Semaglutide is a GLP-1 receptor agonist: it mimics a gut hormone that slows stomach emptying, signals fullness and boosts insulin after meals. Tirzepatide is a dual GIP and GLP-1 receptor agonist, and acting on both hormones is the leading explanation for its larger average effect. Foundayo (orforglipron) is a third type: a small-molecule GLP-1 pill you can take without the fasting rules the Wegovy pill has. All three are prescription-only.
Tirzepatide vs semaglutide side effects: which is easier to tolerate?
Both share a GI-dominant side-effect profile, and in the head-to-head trial the rates were close:
| Side effect | Tirzepatide | Semaglutide |
|---|---|---|
| Nausea | 43.6% | 44.4% |
| Constipation | 27.0% | 28.5% |
| Diarrhea | 23.5% | 23.4% |
| Vomiting | 15.0% | 21.3% |
| Acid reflux (GERD) | 6.1% | 10.6% |
| Stopped because of side effects | 6.1% | 8.0% |
Most of these are worst in the weeks after each dose increase and fade with time. A 2026 pooled analysis of 10 head-to-head studies found no difference in stopping for side effects, but more serious adverse events on tirzepatide (relative risk 1.83) (Clinical Obesity, 2026). Both carry the same boxed warning about thyroid C-cell tumors. For a drug-by-drug ranking, see Which GLP-1 Has the Fewest Side Effects? or our tirzepatide side effects guide.
Why would a doctor prescribe semaglutide instead of tirzepatide?
The averages favor tirzepatide, but prescribers may choose semaglutide for reasons a weight-loss average does not show. What the trials and FDA labels point to:
| If you… | What the evidence points to |
|---|---|
| Want the largest average weight loss | Tirzepatide (Zepbound), from the only head-to-head trial |
| Have had a heart attack or stroke, or have heart disease | Wegovy (injection or pill): approved to lower that risk after the SELECT trial. Zepbound has no heart-risk indication |
| Have obstructive sleep apnea | Zepbound: the first drug approved for it, in adults with obesity |
| Have MASH (fatty liver with fibrosis) | Wegovy has the approval |
| Have type 2 diabetes | The diabetes-labelled versions, Mounjaro (tirzepatide) or Ozempic (semaglutide) |
| Would rather take a pill | Wegovy pill (semaglutide; empty stomach, then wait 30 minutes) or Foundayo (with or without food) |
| Are doing well on semaglutide | Many stay on it; Wegovy HD is an option if weight loss stalls on 2.4 mg |
Coverage often decides it: insurance coverage is inconsistent, and the drug on your plan's formulary can cost far less than the one you'd pick on averages. Not all applicants qualify: the weight-loss labels generally require a BMI of 30 or more, or 27 or more with a weight-related condition. Diabetic? Read our Mounjaro vs Ozempic breakdown. Comparing the pill with the shot? See oral vs injectable semaglutide.
Do you lose more muscle on tirzepatide or semaglutide?
Nobody knows yet: no trial has compared their effect on muscle, and SURMOUNT-5 did not scan body composition. In separate DXA-scan substudies, about a quarter of the weight lost on tirzepatide (SURMOUNT-1) and about two-fifths on semaglutide (STEP 1) was lean mass, but different people and methods make that a weak comparison (review of the substudies). On both drugs most of the loss is fat, and protein plus resistance training is how to protect muscle; see how much protein to eat on a GLP-1.
What does each cost without insurance?
Self-pay brand prices now overlap: Zepbound® approximately $299–$449/month via LillyDirect, against $349 for the Wegovy pen at any dose up to 2.4 mg. Prices rise with the dose for Zepbound and both pills, so the first-year total is the fairer comparison:
| Option | Month 1 | Usual maintenance month | First-year estimate |
|---|---|---|---|
| Zepbound (tirzepatide) | $299 | $449 at 7.5 mg and up | $5,188 |
| Wegovy (semaglutide) | $199 (intro offer) | $349 | $3,888 |
| Wegovy HD (semaglutide 7.2 mg) | Not a starting option | $399 | n/a† |
| Wegovy pill (semaglutide) | $149 | $299 at 9 or 25 mg | $3,338 |
| Foundayo (orforglipron) | $149 | $299 at 9 mg and up | n/a† |
First-year estimates are our arithmetic, not quotes, at each maker's published self-pay prices: Zepbound 1 month at 2.5 mg, 1 at 5 mg, then 10 at 7.5 mg; Wegovy two $199 intro fills, then 10 at $349; Wegovy pill 1 month at 1.5 mg, 1 at 4 mg, then 10 at 9 or 25 mg. †Not estimated: Wegovy HD comes only after 2.4 mg, and Foundayo's lower-dose prices are promotional until Dec 31, 2026. Your prescriber sets the dose. Mounjaro's single-dose pen is $499 a month at every dose through LillyDirect (checked Oct 13, 2026). For every drug and provider, see the 2026 GLP-1 cost guide or the tirzepatide price table.
Can you switch between them?
There is no milligram conversion between them. Switching means a new prescription and restarting at a low introductory dose of tirzepatide: the Zepbound label starts everyone at 2.5 mg for 4 weeks. Going the other way, Wegovy starts at 0.25 mg. Neither label gives a switching schedule, so your prescriber sets the timing. Drawing doses from a vial? The tirzepatide dose calculator and semaglutide dose calculator convert a prescribed dose to syringe units. Full steps: switching from semaglutide to tirzepatide.
What about compounded semaglutide and tirzepatide?
Telehealth companies also sell compounded versions, mixed by state-licensed 503A compounding pharmacies. They are not FDA-approved, have not been reviewed for safety, effectiveness or quality, and are not the same as Zepbound or Wegovy. None of the trial results on this page apply to them. What each one is and where it stands legally in 2026: compounded semaglutide and compounded tirzepatide. They usually cost less, and the FDA has reported dosing errors and adverse events with them (FDA postmarket safety information; FDA human drug compounding). More in our brand vs compounded GLP-1 guide, the compounded semaglutide vs Wegovy comparison and compounded semaglutide vs tirzepatide. For what each version costs without insurance, see our semaglutide price table and GLP-1 options ranked by lowest monthly price.
Related comparisons
- Which GLP-1 Is Most Effective for Weight Loss?
- Which GLP-1 Has the Fewest Side Effects?
- Ozempic vs Wegovy: Same Molecule, Different Uses
- Zepbound vs Ozempic
- Mounjaro vs Ozempic
- Compounded Semaglutide vs Wegovy: Cost and Key Differences
- Compounded Tirzepatide vs Zepbound: Cost and Key Differences
- How Much Does a GLP-1 Cost in 2026?
Frequently asked questions
Is tirzepatide better than semaglutide for weight loss?
On average, yes, tirzepatide is the stronger drug for weight loss: in SURMOUNT-5, the only head-to-head trial, branded tirzepatide averaged 20.2% weight loss at 72 weeks versus 13.7% on semaglutide 2.4 mg. The higher Wegovy HD dose (7.2 mg) averaged 18.7% in a separate trial, so the gap is smaller at that dose.
Which has fewer side effects, tirzepatide or semaglutide?
Neither has a clear edge. In SURMOUNT-5, nausea, diarrhea and constipation rates were nearly identical, vomiting was less common on tirzepatide (15% vs 21%), and 6.1% versus 8.0% stopped because of side effects.
Can you switch from semaglutide to tirzepatide?
Yes, with a new prescription: the Zepbound label starts everyone at 2.5 mg for 4 weeks, and the two drugs do not convert milligram for milligram.
Is Zepbound the same as tirzepatide, and Wegovy the same as semaglutide?
Yes: Zepbound and Mounjaro are brand names for tirzepatide, and Wegovy, Ozempic and Rybelsus are brand names for semaglutide. Compounded versions use the ingredient names but are not FDA-approved and are not the same as the brands.
How much more weight do you lose on tirzepatide vs semaglutide?
About 6.5 percentage points of body weight in SURMOUNT-5 (20.2% vs 13.7%), or roughly 22.8 kg versus 15.0 kg on average. Nearly half of the tirzepatide group lost 20% or more, against about 3 in 10 on semaglutide.
Does tirzepatide or semaglutide have better cardiovascular evidence?
Semaglutide does for weight-loss patients: Wegovy is FDA-approved to lower heart attack, stroke and cardiovascular death risk in adults with heart disease and excess weight, after SELECT showed a 20% relative reduction. Tirzepatide carries a heart-risk indication only for Mounjaro in high-risk type 2 diabetes.
Why would a doctor prescribe semaglutide instead of tirzepatide?
A doctor may choose semaglutide because Wegovy is approved to lower heart attack and stroke risk and to treat MASH liver disease, comes as a daily pill, may be the one insurance covers, or is already working for the patient.
Is Wegovy HD as effective as Zepbound?
Possibly close, but unproven: Wegovy HD averaged 18.7% in STEP UP and Zepbound 20.2% in SURMOUNT-5, and the two have never been compared in the same trial. Wegovy HD is only for people who already tolerate 2.4 mg.
Do you lose more muscle on semaglutide or tirzepatide?
No trial has compared them directly. In separate scan substudies, about a quarter of the weight lost on tirzepatide and about two-fifths on semaglutide was lean mass, but the studies used different people and methods.
Is tirzepatide or semaglutide cheaper without insurance?
Semaglutide usually: at manufacturer self-pay prices, a first year of Wegovy is about $3,888 versus about $5,188 for Zepbound, and the Wegovy pill starts at $149 a month.
The bottom line
On average, tirzepatide still produces more weight loss than semaglutide: 20.2% versus 13.7% in the only head-to-head trial, with nearly twice the share of people losing 20% or more. In 2026, Wegovy HD narrowed that gap for people already on semaglutide. Two pills now offer a needle-free route, brand injection prices converged in the $300s and $400s, and the pills start at $149. Semaglutide keeps the heart-risk evidence; tirzepatide has the sleep apnea approval. See what licensed providers charge → or Compare published GLP-1 prices.
Sources and references
- Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). NEJM 2025; response thresholds and kg from Lilly's May 2025 results release; adverse events from ClinicalTrials.gov NCT05822830
- Wharton S et al. Semaglutide 7.2 mg in adults with obesity (STEP UP). Lancet Diabetes & Endocrinology 2025
- FDA: approval of higher-dose semaglutide (Wegovy HD 7.2 mg), March 2026
- Wegovy (semaglutide) injection and tablets, Prescribing Information, DailyMed, June 2026 (Wegovy HD, Wegovy pill and OASIS 4 results)
- Wegovy® (semaglutide) FDA Prescribing Information, 2026
- Zepbound (tirzepatide) Prescribing Information, DailyMed; Zepbound® (tirzepatide) FDA Prescribing Information, 2024
- FDA: approval of Foundayo (orforglipron), April 2026; Orforglipron, an oral small-molecule GLP-1 receptor agonist, for obesity (ATTAIN-1). NEJM 2025
- FDA: first medication approved for obstructive sleep apnea (Zepbound), December 2024
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. SELECT, NEJM 2023
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. STEP-1, NEJM 2021
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. SURMOUNT-1, NEJM 2022
- Rodriguez PJ et al. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Internal Medicine 2024
- Tirzepatide versus semaglutide: systematic review and meta-analysis of head-to-head studies. Clinical Obesity 2026
- Review of DXA body-composition substudies of GLP-1 medications (PMC, 2026)
- Self-pay prices, checked Oct 11, 2026: LillyDirect Zepbound, LillyDirect Foundayo, Wegovy savings and self-pay (Novo Nordisk)
- FDA: Human Drug Compounding
- FDA: Postmarket Drug Safety Information — GLP-1 compounding concerns
- NIDDK: Prescription Medications to Treat Overweight and Obesity
Trial results on this page are for the FDA-approved branded drugs. Compounded semaglutide and tirzepatide are not FDA-approved, have not been evaluated by the FDA for safety, effectiveness or quality, and are not therapeutically equivalent to Wegovy, Ozempic, Zepbound or Mounjaro. This page summarizes published trials and FDA labels; it is not medical advice, and a licensed prescriber decides which drug and dose fit you. Zepbound®, Mounjaro® and Foundayo™ are trademarks of Eli Lilly; Wegovy® and Ozempic® are trademarks of Novo Nordisk. Nouri is not affiliated with either company. Nouri is a publisher; it does not prescribe or sell any medication.
Disclosure: Nouri may earn a commission when you sign up with some of the providers we link to. It doesn't change what you pay or how we rank providers. Full disclosure.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Nouri is an independent publisher: it does not prescribe, review patient assessments, or sell medication. Talk to a licensed clinician before starting or changing any medication or treatment.
Compare licensed GLP-1 providers
Published cash prices side by side, with the month we checked them and a link to each provider's own site. Nouri doesn't prescribe or sell medication.